8-K: Shuttle Pharmaceuticals Expands Phase 2 Glioblastoma Study with Theradex Systems

Shuttle Pharmaceuticals increases patient enrollment and study sites for its Phase 2 trial of Ropidoxuridine in glioblastoma patients through a change order with Theradex Systems.

Summary

• Shuttle Pharmaceuticals has amended its work order with Theradex Systems to expand its Phase 2 study of Ropidoxuridine for glioblastoma.
• The key changes include increasing the number of patients from 15 to 16 to include a replacement patient.
• The number of study sites has increased from four to six.
• The change order also adds an investigator site and safety teleconference to allow for medical monitor review of safety data.
• There are small budget increases due to the increased number of sites and travel costs for site monitoring.
• The total cost is limited to $5,308,294.
• Protocol amendments version 2.0 and 3.0 have been added.
• One on-site qualification visit was removed and replaced with a remote visit.

Sentiment

Score: 7

Explanation: The document indicates positive progress in the clinical trial, with an expansion of the study and continued investment. However, the increased costs and potential risks associated with the expansion temper the overall sentiment.

Positives

• The expansion of the Phase 2 study suggests confidence in the potential of Ropidoxuridine.
• The inclusion of a replacement patient ensures the study maintains its target enrollment.
• The addition of investigator sites and safety teleconferences enhances patient safety monitoring.
• The activation of two sites earlier than anticipated (UNC and Georgetown) indicates efficient study progress.

Risks

• Increased costs associated with the expanded study may impact the company's financial resources.
• Delays in study timelines could occur due to the increased number of patients and sites.
• Protocol amendments may introduce complexities and potential delays in the study process.

Future Outlook

The change order suggests continued progress and investment in the Phase 2 study, with an estimated total study duration of 53 months.

Industry Context

Expanding clinical trials is a common practice in the pharmaceutical industry to ensure robust data and address unforeseen challenges. CROs like Theradex Systems play a crucial role in supporting these trials.

Comparison to Industry Standards

• Increasing the number of patients in a clinical trial is a standard practice when a patient drops out or to increase statistical power.
• Adding clinical trial sites is a common strategy to accelerate patient enrollment.
• Using CROs like Theradex is a common industry practice to manage clinical trials.

Stakeholder Impact

• Shareholders may view the expansion of the Phase 2 study as a positive sign of progress.
• Patients with glioblastoma may benefit from the increased access to the clinical trial.
• Theradex Systems will benefit from the increased scope of work and associated revenue.

Next Steps

• Shuttle Pharmaceuticals will continue to work with Theradex Systems to implement the changes outlined in the change order.
• The company will proceed with activating the additional study sites and enrolling the replacement patient.
• The company will continue to monitor the safety data and implement protocol amendments as needed.

Key Dates